- Trials with a EudraCT protocol (7,358)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (375)
7,358 result(s) found for: Chronic.
Displaying page 1 of 368.
EudraCT Number: 2004-002977-22 | Sponsor Protocol Number: 108/2004/U | Start Date*: 2004-09-28 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: A PHASE II STUDY OF VELCADE BORTEZOMIB - PS341 IN THE TREATMENT OF PATIENTS OVER 18 YEARS WITH Ph LEUKEMIA | |||||||||||||
Medical condition: patients over 18 years with Ph leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001361-29 | Sponsor Protocol Number: CLWP 001 2008 | Start Date*: 2009-10-08 | |||||||||||
Sponsor Name:EBMT (European group for Blood and Marrow Transplantation) | |||||||||||||
Full Title: Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation | |||||||||||||
Medical condition: chronic myeloid leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001334-18 | Sponsor Protocol Number: CarPAs | Start Date*: 2020-09-10 | ||||||||||||||||
Sponsor Name:Associazione Italiana Pazienti Leucemia Mieloide Cronica (AIPLMC) | ||||||||||||||||||
Full Title: Cardiovascular assessment of Ponatinib as treatment option in chronic phase chronic myeloid leukemia after failure of Imatinib and Bosutinib (CarPAs) | ||||||||||||||||||
Medical condition: Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000899-28 | Sponsor Protocol Number: CAMN107CNL08T | Start Date*: 2018-09-04 | |||||||||||||||||||||
Sponsor Name:Albert Schweitzer Hospital | |||||||||||||||||||||||
Full Title: Dipeptidylpeptidase IV (CD26) on Philadelphia-positive leukemic stem cells (LSC) as marker and novel therapeutic target in chronic myeloid leukemia (CML). | |||||||||||||||||||||||
Medical condition: Chronic myeloid leukemia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) BE (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004347-12 | Sponsor Protocol Number: ICT-10 | Start Date*: 2016-03-05 | |||||||||||
Sponsor Name:Hybrigenics SA | |||||||||||||
Full Title: Exploratory Study of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study | |||||||||||||
Medical condition: Residual disease in Chronic Myeloid Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000597-22 | Sponsor Protocol Number: GIMEMACML0307 | Start Date*: 2007-06-20 | |||||||||||
Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO | |||||||||||||
Full Title: The protein tyrosine kinase inhibitor nilotinib as first-line treatment of Ph+ chronic myeloid leucemia (CML) in early chronic phase: a Phase II exploratory, multicenter study | |||||||||||||
Medical condition: Ph+ CML in early chronic phase | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003780-50 | Sponsor Protocol Number: B1871008 | Start Date*: 2008-07-30 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA | |||||||||||||
Full Title: A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | |||||||||||||
Medical condition: Chronic myelogenous leukemia (CML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) GB (Completed) BE (Completed) ES (Completed) LV (Completed) LT (Completed) FR (Completed) IT (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006881-40 | Sponsor Protocol Number: AURA-6202-005 | Start Date*: 2007-01-31 | |||||||||||
Sponsor Name:NERVIANO MEDICAL SCIENCES | |||||||||||||
Full Title: A pilot Phase II study of PHA-739358 in patients with Chronic Myeloid Leukemia relapsing on Gleevec or c-ABL therapy | |||||||||||||
Medical condition: Treatment of Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006185-15 | Sponsor Protocol Number: SPIRIT 2 | Start Date*: 2008-04-22 | |||||||||||
Sponsor Name:Newcastle-upon-Tyne Hospitals NHS Trust | |||||||||||||
Full Title: STI571 Prospective International RandomIsed Trial 2 - A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in pati... | |||||||||||||
Medical condition: newly-diagnosed chronic-phase Chronic myeloid leukaemia (CML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004384-19 | Sponsor Protocol Number: GIMEMA CML0408 | Start Date*: 2008-07-29 | |||||||||||
Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO | |||||||||||||
Full Title: Front-line treatment of Philadelphia positive (Ph pos), BCR-ABL positive, chronic myeloid leukemia (CML) with two tyrosine kinase inhibitors (TKI) (Nilotinib and Imatinib). A phase II exploratory m... | |||||||||||||
Medical condition: Philadelphia positive (Ph pos), BCR-ABL positive, Chronic Myeloid Leukemia (CML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003674-26 | Sponsor Protocol Number: MK0457-009 | Start Date*: 2007-09-03 | |||||||||||
Sponsor Name:MERCK SHARP DOHME | |||||||||||||
Full Title: A Phase I Dose Escalation of MK-0457 in Combination With Dasatinib in Patients With Refractory Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. | |||||||||||||
Medical condition: Patients with Refractory Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006189-40 | Sponsor Protocol Number: GIMEMA CML0206 | Start Date*: 2007-03-27 | |||||||||||
Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL ADULTO | |||||||||||||
Full Title: PHASE II MULTICENTER STUDY OF P210-B3A2 DERIVED PEPTIDE VACCINE IN CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITH PERSISTENT MOLECULAR RESIDUAL DISEASE DURING IMATINIB TREA... | |||||||||||||
Medical condition: CHRONIC MYELOID LEUKEMIA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001603-42 | Sponsor Protocol Number: AIL0115 | Start Date*: 2015-09-22 | |||||||||||
Sponsor Name:AIL CATANIA ASSOCIAZIONE ITALIANA CONTRO LEUCEMIE-LINFOMI E MIELOMA ONLUS | |||||||||||||
Full Title: “Arrest Imatinib or Dasatinib in CML patients with Deep Molecular Responses” (AID MORE) | |||||||||||||
Medical condition: Chronic phase CML patients with BCR-ABL/ABLIS transcript levels below MR3 (<0.1%) and above MR4.5 (>0.0032%) at the time of accrual. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001380-61 | Sponsor Protocol Number: CSTI5710102E2 | Start Date*: 2005-04-15 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: An extension to a phase II open label study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast c... | |||||||||||||
Medical condition: Ph+ CML in myeloid blast crisis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001381-14 | Sponsor Protocol Number: CSTI5710109E2 | Start Date*: 2005-08-02 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: An extension to a phase II study to determine the safety and the anti- leukemic effects of STI571 in adults patients with Philadelphia chromosome positive leukemia including acute lymphoblastic le... | |||||||||||||
Medical condition: Philadelphia chromosome positive leukemia including acute lymphoblastic leukemia, acute myeloid leukemia and accelerate phase myeloid leukemia. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007094-20 | Sponsor Protocol Number: IB 2009-07 | Start Date*: 2009-07-17 | |||||||||||
Sponsor Name:Institut Bergonié | |||||||||||||
Full Title: Étude multicentrique de phase III évaluant L’efficacité d’une stratégie d’adaptation de dose de l’imatinib mésylate sur la réponse moléculaire chez des patients présentant une leucémie myéloïde chr... | |||||||||||||
Medical condition: Patients présentant une leucémie myéloïde chronique en phase chronique (LMCPC) traités par IM depuis au moins 2 ans, en réponse cytogénétique complète depuis au moins 1 an, avec une maladie résidue... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002850-26 | Sponsor Protocol Number: NL72928.078.20 | Start Date*: 2020-07-20 | |||||||||||||||||||||
Sponsor Name:Albert Schweitzer Hospital | |||||||||||||||||||||||
Full Title: Vaccination response to pneumococcal antigen as novel predictor for successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: the vaccinSTOP study. | |||||||||||||||||||||||
Medical condition: Chronic myeloid leukemia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018339-16 | Sponsor Protocol Number: CSTI571ADE75T-GMIHO-005/2009 | Start Date*: 2010-07-19 | |||||||||||
Sponsor Name:GMIHO mbH | |||||||||||||
Full Title: CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A prospective, multi-center, phase IV study to assess the compliance in patients with Philadelphia chromosome-p... | |||||||||||||
Medical condition: CML - chronic myelogenous leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000602-17 | Sponsor Protocol Number: CABL001A2001B | Start Date*: 2021-08-10 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit fr... | |||||||||||||
Medical condition: CML-CP (at the end of parent study) who are currently participating in an asciminb Novartis sponsored study (parent study) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) DE (Ongoing) BG (Ongoing) IT (Ongoing) PT (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003502-16 | Sponsor Protocol Number: DasaHIT | Start Date*: 2016-08-11 | |||||||||||
Sponsor Name:Friedrich-Schiller-Universität Jena | |||||||||||||
Full Title: Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors... | |||||||||||||
Medical condition: Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.